Friedrich, Christian
Francke, Klaus
Birring, Surinder S.
van den Berg, Jan Willem K.
Marsden, Paul A.
McGarvey, Lorcan
Turner, Alice M.
Wielders, Pascal
Gashaw, Isabella
Klein, Stefan
Morice, Alyn H.
Clinical trials referenced in this document:
Documents that mention this clinical trial
The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial
https://doi.org/10.1186/s12931-023-02384-8
Article History
Received: 22 December 2022
Accepted: 7 March 2023
First Online: 11 April 2023
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki. The protocol for this study (EudraCT 2018-000129-29; clinicaltrials.gov NCT03535168) was approved by the relevant independent ethics committees (see Additional fileInternalRef removed) before the start of the study. All study participants gave their written informed consent before entry into the study.
: Not applicable.
: CF, KF, and SK are employees of Bayer AG, the company that developed the study drug and sponsored the study and the preparation of this manuscript. IG was employed by Bayer AG when the study was planned and conducted. AHM has received grant funding and personal fees from Merck, Shionogi, Bellus, and Bayer. PAM has received industry-sponsored research funding. AMT, JWKvdB, LMcG, PW, and SSB have no potential conflicts of interest to declare.